Burning rock reports unaudited fourth quarter and full year 2024 financial results

Guangzhou, china, march 25, 2025 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended december 31, 2024. 2024 business overview and recent updates corporate updates completed profitability-driven organizational optimization, execution towards profitability well underway early detection   thunder study for 6-cancer test was included in the diagnosis and treatment guidelines for primary liver cancer (2024 edition) and the expert consensus on detection and clinical application of tumor dna methylation markers (2024 edition), showing an impressive performance of elsa-seq using cfdna in cancer detection and origin prediction.
BNR Ratings Summary
BNR Quant Ranking